GoodRx (NASDAQ:GDRX) Price Target Cut to $10.00 by Analysts at Citigroup

GoodRx (NASDAQ:GDRX) had its price target decreased by Citigroup from $11.00 to $10.00 in a research report released on Friday, Benzinga reports. Citigroup currently has a buy rating on the stock.

A number of other research firms have also recently issued reports on GDRX. TD Cowen increased their price target on GoodRx from $14.00 to $16.00 and gave the stock a buy rating in a report on Thursday, May 16th. UBS Group dropped their price objective on shares of GoodRx from $9.00 to $8.50 and set a neutral rating on the stock in a report on Friday. Barclays upped their price target on GoodRx from $9.00 to $10.00 and gave the stock an overweight rating in a research note on Monday, May 20th. Raymond James raised shares of GoodRx from an outperform rating to a strong-buy rating and set a $10.00 price objective on the stock in a research note on Friday. Finally, Morgan Stanley boosted their target price on shares of GoodRx from $7.00 to $9.50 and gave the stock an equal weight rating in a research report on Monday, June 10th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, GoodRx presently has a consensus rating of Moderate Buy and a consensus target price of $9.36.

GoodRx Trading Up 2.9 %

Shares of GoodRx stock traded up $0.20 on Friday, hitting $7.21. The stock had a trading volume of 3,233,761 shares, compared to its average volume of 1,471,224. The stock has a 50 day moving average of $8.27 and a 200 day moving average of $7.38. The company has a debt-to-equity ratio of 1.02, a quick ratio of 6.29 and a current ratio of 6.29. GoodRx has a twelve month low of $4.14 and a twelve month high of $9.26. The firm has a market capitalization of $2.71 billion, a P/E ratio of -721.00, a PEG ratio of 4.08 and a beta of 1.39.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings results on Thursday, May 9th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.01). The company had revenue of $197.88 million during the quarter, compared to analyst estimates of $196.20 million. GoodRx had a negative net margin of 0.86% and a positive return on equity of 3.45%. Sell-side analysts expect that GoodRx will post 0.17 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GoodRx

Hedge funds and other institutional investors have recently modified their holdings of the stock. GSA Capital Partners LLP purchased a new position in shares of GoodRx in the first quarter valued at about $1,638,000. Rubric Capital Management LP purchased a new stake in GoodRx in the 4th quarter worth approximately $39,348,000. Mirae Asset Global Investments Co. Ltd. grew its position in shares of GoodRx by 61.1% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 181,512 shares of the company’s stock worth $1,289,000 after buying an additional 68,835 shares during the last quarter. Jupiter Asset Management Ltd. purchased a new position in shares of GoodRx during the first quarter valued at approximately $707,000. Finally, ClariVest Asset Management LLC purchased a new position in shares of GoodRx during the first quarter valued at approximately $1,091,000. Institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.